In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3770-3776

  Binaschi, Monica ^a   Farinosi, Rosalba ^a   Borgnetto, M Evelina ^a   Capranico, Giovanni ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEMETHOXY 3' DEAMINO 3' HYDROXY 4' EPIDOXORUBICIN; 4 DEMETHOXY 3' DEAMINO 4 DEOXY 4' EPIAMINODAUNORUBICIN; ANTHRACYCLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN HL 60; CONTROLLED STUDY; DNA CLEAVAGE; DROSOPHILA; DRUG MECHANISM; DRUG STRUCTURE; ENZYME SPECIFICITY; GENE CLUSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANIMALS; ANTHRACYCLINES; BASE SEQUENCE; CELL LINE; CELL NUCLEUS; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DROSOPHILA; HISTONES; HUMANS; ISOENZYMES; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; SUBSTRATE SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 0034660851     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
2. DNA topoisomerases
3. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
4. Drugs acting on DNA topoisomerases: Recent advances and future perspectives
5. Cell death induced by topoisomerase-targeted drugs: More questions than answers
6. Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity
7. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells
8. Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage
9. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin. Heterogeneous localization and reversibility
10. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons
11. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety
12. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance
13. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase II α in yeast
14. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II β
15. Human DNA topoisomerase IIα-dependent DNA cleavage and yeast cell killing by anthracycline analogues
16. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase II β inhibitors in yeast
17. In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics
18. Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases
19. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180)
20. Topoisomerase poisoning activity of novel disaccharide anthracyclines
21. Resolving the role of topoisomerase II in chromatin structure and function
22. The distribution of topoisomerase II cleavage sites in Simian virus 40 DNA and the effects of drugs
23. Characterization of covalent Adriamycin-DNA adducts
24. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells
25. Diversity of DNA topoisomerases I and inhibitors
26. Mapping in vivo topoisomerase 1 sites on simian virus 40 DNA: Asymmetric distribution of sites on replicating molecules
27. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors
28. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions
29. Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin
30. Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase
31. Gene and human tumour cell line specific differences in nitrogen mustard induced DNA alkylation and interstrand crosslinking frequencies
32. The carbohydrate domain of calicheamicin γ II determines its sequence specificity for DNA cleavage
33. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin
34. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands
35. Inhibition of Ets-I DNA binding and ternary complex formation between Ets-1.NF-κB and DNA by a designed DNA-binding ligand
36. The mitomycin bioreductive antitumor agents: Crosslinking and alkylation of DNA as the molecular basis of their activity
37. Modulation of mitomycin cross-linking by DNA bending in the Escherichia coli CAP protein-DNA complex
38. Binding of lxrl, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo
39. Photoreactivity of platinum (II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins
40. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities